COMPARISON OF APPROVAL DATES OF NEW SUBSTANCES BETWEEN THE UNITED STATES OF AMERICA (FOOD AND DRUG ADMINISTRATION, FDA) AND EUROPE (EUROPEAN MEDICINES AGENCY, EMA)

被引：0

作者：

Batscheider, A. ^{[1
]}

Weiss, K. ^{[2
]}

Schnauffer, D. ^{[3
]}

Al-Khalaf, A. ^{[3
]}

Greiner, R. A. ^{[3
]}

Shlaen, E. ^{[3
]}

机构：

[1] IQVIA Commercial GmbH & Co OHG, Munich, BY, Germany

[2] IQVIA Commercial GmbH & Co OHG, Munich, Bavaria, Germany

[3] IQVIA Commercial GmbH & Co OHG, Munich, Germany

来源：

VALUE IN HEALTH | 2023年 / 26卷 / 12期

关键词：

D O I：

暂无

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PT25

引用

页码：S293 / S293

页数：1

共 49 条

[21] New drug submissions in Canada and a comparison with the Food and Drug Administration and the European Medicines Agency: Cross-sectional analysis
Lexchin, Joel
PLOS ONE, 2023, 18 (06):
[22] Evolution and current status of United States Food and Drug Administration and European Medicines Agency regulatory guidance for studies of nosocomial pneumonia
Talbot, George H.
CURRENT OPINION IN CRITICAL CARE, 2018, 24 (05) : 379 - 384
[23] Comparison of hydroxyethyl starch regulatory summaries from the Food and Drug Administration and the European Medicines Agency
Wiedermann C.J.
Eisendle K.
Journal of Pharmaceutical Policy and Practice, 10 (1)
[24] Food and Drug Administration vs European Medicines Agency: Review times and clinical evidence on novel drugs at the time of approval
Joppi, Roberta
Bertele, Vittorio
Vannini, Tommaso
Garattini, Silvio
Banzi, Rita
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 86 (01) : 170 - 174
[25] Comparison of Drug Approvals in Europe Versus the United StatesAn Analysis of Discrepancies Between Drug Products Reviewed by EMA and FDA
Robert W. Makuch
Ruizhi Shi
Therapeutic Innovation & Regulatory Science, 2014, 48 : 362 - 366
[26] An Analysis of Regulatory Timing and Outcomes for New Drug Applications Submitted to Swissmedic: Comparison With the US Food and Drug Administration and the European Medicines Agency
Petra Dörr
Alison Wadworth
Tina Wang
Neil McAuslane
Lawrence Liberti
Therapeutic Innovation & Regulatory Science, 2016, 50 : 734 - 742
[27] An Analysis of Regulatory Timing and Outcomes for New Drug Applications Submitted to Swissmedic: Comparison With the US Food and Drug Administration and the European Medicines Agency
Dorr, Petra
Wadworth, Alison
Wang, Tina
McAuslane, Neil
Liberti, Lawrence
THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2016, 50 (06) : 734 - 742
[28] THE RISE OF ORPHAN DRUGS IN EUROPE VS THE UNITED STATES: COMPARING ORPHAN DRUG DESIGNATIONS BETWEEN THE EMA AND FDA
Mildred, M.
Lee, S.
VALUE IN HEALTH, 2015, 18 (07) : A677 - A677
[29] United States Food and Drug Administration Advisory Committee outcomes and agency approval analysis from 2010 to 2015
McCormack, Zachary
JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2018, 58 (05) : 530 - 533
[30] Comparison between European Medicines Agency and US Food and Drug Administration in Granting Accelerated Marketing Authorizations for Covid-19 Medicines and their Utilized Regulations
Ghadanian, Marina
Schafheutle, Ellen
THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2024, 58 (01) : 79 - 113

← 1 2 3 4 5 →